Ligand Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Ligand Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ligand Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ligand Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ligand Pharmaceuticals Inc (Ligand) is a biopharmaceutical royalty aggregator. It majorly focuses on funding programs in mid- to late-stage drug development for economic rights, purchasing royalty rights in the development stage or commercial biopharmaceutical products, and licensing our technology to help partners discover and develop medicines for various conditions, including cancer, kidney disease, and infectious diseases. It offers infrastructure-light royalty-generating IP technology platforms, known as Captisol, a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs, and NITRICIL, an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. The company operates active DMFs in Japan, China, Canada, and the US. Ligand is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 200, 555 Heritage Drive, Jupiter, Florida, 33458
Website
www.ligand.com
Telephone
1 858 5507500
No of Employees
47
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LGND (NASD)
Revenue (2024)
$215.0M
28.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
3186.6%
(2024 vs 2023)
Market Cap*
$6.0B
Net Profit Margin (2024)
XYZ
2,501.7%
(2024 vs 2023)
* As of and is in US$
Ligand Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Technologies: | Ligand |
| Chemically Modified Cyclodextrin | BEPro |
| Nitric Oxide's Naturally Occurring Antimicrobial and Immunomodulatory | Captisol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In September, the company entered into an agreement to acquire royalty rights associated with net sales of Ryjunea in Europe, the Middle East, and Africa from Sydnexis, Inc. |
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired XOMA Royalty Corp for US$739 million. |
| 2026 | Regulatory Approval | In April, the company's partner, Travere Therapeutics, Inc., secured approval from the U.S. Food and Drug Administration for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome. |
Competitor Comparison
| Key Parameters | Ligand Pharmaceuticals Inc | Halozyme Therapeutics Inc | ANI Pharmaceuticals Inc | TransGenic Group Inc | AbCellera Biologics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | Canada |
| City | Jupiter | San Diego | Baudette | Fukuoka | Vancouver |
| State/Province | Florida | California | Minnesota | Fukuoka | British Columbia |
| No. of Employees | 47 | 423 | 970 | 227 | 562 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John W. Kozarich, PhD | Chairman | Executive Board | 2007 | 75 |
| Todd C. Davis | Chief Executive Officer; Director | Executive Board | 2022 | 64 |
| Tavo Espinoza | Chief Financial Officer | Senior Management | 2022 | 54 |
| Andrew Reardon | Chief Legal Officer | Senior Management | 2022 | 50 |
| Keith Marschke, PhD | Senior Vice President, Biology and Scientific Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer